SGO Issues Jan. 23, 2015
SGO Board of Directors and Foundation Council open election
2015 clinical practice fact sheets now on SGO website
Ovarian cancer patterns of care in Gynecologic Oncology
Updated SGO genetics statement in Gynecologic Oncology
Ensure membership is current to create Health Advance account
Orr serving as chair of Florida Board of Medicine
The 2015 SGO Board of Directors and Foundation Council open election is now underway. All SGO members who are eligible to vote should have received an email from firstname.lastname@example.org on Monday, Jan. 12.The list of candidates for each position, including biographical information, personal statements and photos, is available for your consideration. Please take some time to review the candidates’ statements prior to casting your vote. Candidate information is also available on the ballot. Voting ends at 11:59 p.m. CST on Friday, Feb. 13.
The SGO website now has three updated SGO fact sheets on the Clinical Practice Management page: 2015 SGO Fact Sheet: Electronic Health Records, 2015 SGO Fact Sheet: Physician Quality Reporting System and 2015 SGO Fact Sheet: Physician Value-Based Payment Modifier.
The January 2015 issue of Gynecologic Oncology includes two SGO articles on ovarian cancer patterns of care: Ovarian cancer in the United States: Contemporary patterns of care associated with improved survival by William A. Cliby, MD, et al., and an accompanying editorial by Barbara A. Goff, MD, entitled Measuring Ovarian Cancer Care: Why Are We Still Failing?
Dr. Cliby, a gynecologic oncologist from the Mayo Clinic College of Medicine, noted that ovarian cancer patterns of care are a national health care delivery issue, and that the number and proportion of U.S. cancer centers treating very few cases of ovarian cancer on an annual basis was a surprise to him and his fellow authors, Matthew A. Powell, MD; Noor Al-Hammadi, MD; Ling Chen, MD; J. Philip Miller, MD; Phillip Y. Roland, MD; David G. Mutch, MD; and Robert E. Bristow, MD.
“Approximately two-thirds of cancer centers treat one to eight cases a year; some of this reflects the rural nature of our country and relative lack of efforts to centralize complex care,” he said. “We do not doubt that these lower volume centers are doing their best in difficult situations, but in a disease as complex as ovarian cancer, there are benefits to expertise gained through teams and experience. I would not expect most of the very low volume centers to have gynecologic oncology specialists.”
Dr. Cliby added that the low volume centers also had more cases excluded in their analysis due to missing or inconsistent data, but as the paper demonstrates even among high volume centers adherence to the National Comprehensive Cancer Network guideline recommendations remains poor.
Referring to Dr. Goff’s accompanying editorial, which poses the question why so many ovarian cancer patients in the U.S. don’t get the basic care that is associated with the best survival, Dr. Cliby commented that as a specialty society SGO should help direct efforts towards centralizing care when it makes sense and better coordinating care for times when it must be delivered locally in more resource-limited settings.
“Issues we typically think of as outside of medicine such as transportation, temporary housing costs, time away from home, infrastructure to promote team work across centers, are all critical barriers that must be addressed if we hope to legitimize the call toward centralization to higher volume centers,” he said.
The product of a nine-month team effort, the SGO Clinical Practice Committee has published the Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions in the January 2015 issue of Gynecologic Oncology, written by lead author Johnathan M. Lancaster, MD, PhD, and C. Bethan Powell, MD; Lee-may Chen, MD; and Debra L. Richardson, MD.
Dr. Chen, from the University of California, San Francisco, noted that the 2015 statement is an update of SGO’s 2007 statement on genetic testing.
“During that time much has changed, including the 2013 Supreme Court’s decision on gene patents, the expansion of technology that can be applied to genetic testing, including panel testing for genes–in addition to BRCA1/2–that may influence a patient’s risk of a GYN cancer,” she said.
Dr. Chen added that after the SGO statement went to press in 2014, the FDA approval of olaparib and its BRCA1/2-based companion diagnostic for ovarian cancer were also important changes to the landscape of genetic testing.
“Knowledge of BRCA1/2-status for patients with ovarian cancer now has meaningful actionable clinical utility, reinforcing our position that all women with high-grade epithelial ovarian/tubal/peritoneal cancer should undergo genetic assessment at the time of their initial cancer diagnosis,” said Dr. Chen. “Clearly, the pace of discovery in hereditary cancer genetics, and the impact these discoveries are having on clinical care will mandate that position statements such as these are reviewed and revised on a regular basis in future.
“As the state of the art evolves, genetic assessment is no longer only about quantification of disease risk, but rather now represents a key component of a comprehensive individualized management plan for women battling (or at risk for) gynecologic cancer,” she said.
ScienceDirect access to Gynecologic Oncology is now being supplemented by a more customized platform for SGO member subscribers. Full, Associate, Candidate and International Tier 1 members automatically receive the journal with their membership; all other members can purchase a subscription to the journal at a discounted rate of $121 per year.
The new platform, called Health Advance, offers even more online functionality to provide SGO members with an optimal user experience. In order to set up your Health Advance account, follow the directions in this one-page document.
The ScienceDirect links will remain live in perpetuity as ScienceDirect remains the online platform for the journal’s institutional subscribers. Once you establish your Health Advance account, you will be able to take advantage of the following features and benefits:
- Customized Gynecologic Oncology home page with links to journal information as well as SGO events and social media feeds
- Access issues of Gynecologic Oncology from volume 1, issue 1 (1973) to the present in HTML and PDF format
- Access Articles-in-Press as they’re published
- Browse through articles or carry out specific searches
- Semantic searching technology across Gynecologic Oncology’s content and – if required – all other journals on Health Advance, with the ability to save searches and set up search alerts
- Set up alerts for new issues and new Articles-in-Press
- Easy access to multimedia, such as Gynecologic Oncology’s Surgical Films series
- Export and download figures and tables from individual articles, together with citation information
- Ability for the editorial team to set up collections of content, for example, collections by topic
In order to enjoy the benefit of this enhanced functionality with the Health Advance platform, please ensure that your SGO membership is current. Click here to renew your member dues. If you have any questions regarding your membership status, contact SGO at email@example.com.
On Jan. 1, SGO Past President James W. Orr, Jr., MD, FACOG, FACS began his six-month term as chair of the Florida Board of Medicine. Dr. Orr has served on the Florida Board of Medicine since 2010. In 2013 he was the board’s Vice Chair. Dr. Orr is Medical Director for Southwest Florida’s Regional Cancer Center at Lee Memorial Hospital System in Fort Myers, FL. He is a past president of the Florida Society of Gynecologic Oncology and the Florida Obstetrical and Gynecologic Society.